 | • レポートコード：MRC-IM30201 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、142ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の調査レポートによると、世界のリポソームドキソルビシン市場規模は2021年に11億ドルに達しました。今後、2027年には16億ドルになり、2022年から2022年の間に年平均6.4％成長すると予測しています。本調査レポートでは、リポソームドキソルビシンの世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、製品別（ドキシル/Caelyx、リポドックス、ミオセット、その他）分析、用途別（白血病、骨肉腫、乳がん、子宮内膜がん、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.などが含まれています。 ・序論 ・調査範囲・手法 ・エグゼクティブサマリー ・イントロダクション ・世界のリポソームドキソルビシン市場規模：製品別 - ドキシル/Caelyxの市場規模 - リポドックスの市場規模 - ミオセットの市場規模 - その他製品の市場規模 ・世界のリポソームドキソルビシン市場規模：用途別 - 白血病における市場規模 - 骨肉腫における市場規模 - 乳がんにおける市場規模 - 子宮内膜がんにおける市場規模 - その他用途における市場規模 ・世界のリポソームドキソルビシン市場規模：地域別 - 北米のリポソームドキソルビシン市場規模 - アジアのリポソームドキソルビシン市場規模 - 欧州のリポソームドキソルビシン市場規模 - 中南米のリポソームドキソルビシン市場規模 - 中東・アフリカのリポソームドキソルビシン市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global liposomal doxorubicin market size reached US$ 1.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 1.6 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.
Liposomal Doxorubicin Market Trends:
The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product and application.
Breakup by Product:
Doxil/Caelyx
Lipodox
Myocet
Others
Breakup by Application:
Leukemia
Bone Sarcoma
Breast Cancer
Endometrial Cancer
Kidney Cancer
Multiple Myeloma
Kaposi Sarcoma
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.
Key Questions Answered in This Report:
How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global liposomal doxorubicin market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global liposomal doxorubicin market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Liposomal Doxorubicin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Doxil/Caelyx
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Lipodox
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Myocet
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Leukemia
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Bone Sarcoma
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Breast Cancer
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Endometrial Cancer
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Kidney Cancer
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Multiple Myeloma
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Kaposi Sarcoma
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Baxter International Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Cipla Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Johnson & Johnson
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Merck KGaA
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Pfizer Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Sun Pharmaceutical Industries Ltd
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Teva Pharmaceutical Industries Ltd
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 TTY Biopharm Company Limited
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Zydus Cadila
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2021
Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2021
Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2021
Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2021
Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis